BCI
RNAM

Brinker Capital Investments’s Avidity Biosciences RNAM Stock Holding History

Brinker Capital Investments’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,827
Closed -$1.34M – 2178
2025
Q3 		$1.34M Buy
30,827
+8,382
+37% +$339K 0.01% 1060
2025
Q2 		$637K Sell
22,445
-441
-2% -$13.1K 0.01% 1404
2025
Q1 		$676K Buy
22,886
+12,197
+114% +$380K 0.01% 1265
2024
Q4 		$311K Sell
10,689
-949
-8% -$39.7K ﹤0.01% 1545
2024
Q3 		$535K Buy
+11,638
New +$505K 0.01% 1311

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brinker Capital Investments's RNAM Position: Q4 2025 in Review

Brinker Capital Investments sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 30,827 shares — an estimated $1.34M sold.

Brinker Capital Investments first reported a position in RNAM in Q3 2024 and held it in 5 quarters. The position peaked at $1.34M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Brinker Capital Investments reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Brinker Capital Investments sold 30,827 Avidity Biosciences shares in Q4 2025, an estimated $1.34M.
  • Brinker Capital Investments first reported a position in Avidity Biosciences in Q3 2024 and held it in 5 quarters.
  • Brinker Capital Investments's Avidity Biosciences position peaked at $1.34M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Brinker Capital Investments's 13F filing for Q4 2025, filed 12 Feb 2026.